SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building on momentum across i…
Si-Bone (SIBN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.…
● GlobeNewsWireNov 2, 2026 · 16:09 ETCOMPANY'S OWN WORDS
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million, representing growth of 14.5% …
● GlobeNewsWireOct 29, 2026 · 17:43 ETCOMPANY'S OWN WORDS
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that…
● GlobeNewsWireOct 19, 2026 · 16:09 ETCOMPANY'S OWN WORDS
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it wil…
Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued
On October 12, 2026, SI-BONE Inc (SIBN) shares rose 3.8% to a current price of $20.10. This movement comes amid a 52-week range that saw a high of $21.89 and a…
Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuati…
● GlobeNewsWireSep 28, 2026 · 16:09 ETCOMPANY'S OWN WORDS
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone…
● GlobeNewsWireAug 31, 2026 · 16:09 ETCOMPANY'S OWN WORDS
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced t…
● Zacks Investment ResearchAug 24, 2026 · 10:56 ET
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings…
Kept in their own lane. A press release is the company talking, not reporting.
Tied to events
No upcoming events in the feeds.
Most covered today
Quiet tape today.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.